A Simple and Sensitive LC‐MS/MS Method for the Determination of Mobocertinib and Its Metabolite Desmethyl‐Mobocertinib in Human Plasma and Its Application to Clinical Pharmacokinetic Study
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.6063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Fan Tang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jingjiang People's Hospital Affiliated to Yangzhou University, Jingjiang, Jiangsu Province, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry. Die Arbeit nennt 14 Literaturangaben. Gefördert von: Qinglan Project of Jiangsu Province of China, Project of Outstanding Yong Backbone Teacher at Yangzhou Polytechnic College.
Abstract (Originalsprache)
Mobocertinib is a potent selective tyrosine kinase inhibitor approved for the treatment of non–small cell lung cancer with activating EGFR exon 20 insertions. The aim of this study was to develop a procedure for liquid chromatography tandem mass spectrometry (LC‐MS/MS) for the determination of mobocertinib and its metabolite desmethyl‐mobocertinib in human plasma. The human plasma samples were precipitated with acetonitrile and analyzed using a Waters ACQUITY BEH C 18 column coupled to a triple quadrupole mass spectrometer. Separation was executed using the acetonitrile–0.1% formic acid solution with gradient elution, at a flow rate of 0.4 mL/min. Mobocertinib and desmethyl‐mobocertinib were monitored by multiple reaction monitoring (MRM) with m / z 586.5 > 72.2 and 572.4 > 473.2, respectively. The procedure demonstrated excellent linearity ( r > 0.997) within the concentration range of 0.1–200 ng/mL for both analytes. Precision in relative standard deviation was < 9.37% for mobocertinib and < 12.03% for desmethyl‐mobocertinib. Accuracy in relative error was within −7.23% to 9.18% for mobocertinib and −2.78% to 9.87% for desmethyl‐mobocertinib. Extraction recovery was > 80% for both analytes. The validated LC‐MS/MS method was successfully applied to the pharmacokinetic study of mobocertinib and desmethyl‐mobocertinib in healthy human volunteers with K 2 EDTA as anticoagulant after a single dose of mobocertinib (160 mg).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jingjiang People's Hospital Affiliated to Yangzhou University, Jingjiang, Jiangsu Province, China.
- Department of Medical Science, Yangzhou Polytechnic College, Yangzhou, Jiangsu Province, China.
- Yangzhou University Medical College, Jiangsu Key Laboratory of Experimental & Translational Non-coding RNA Research, Institute of Translational Medicine, Yangzhou University, Yangzhou, Jiangsu Province, China.
ORCID-Profile: Fan Tang, Hong Cheng
Förderung
- Qinglan Project of Jiangsu Province of China
- Project of Outstanding Yong Backbone Teacher at Yangzhou Polytechnic College
Zitieren
APA
Tang, F., Hou, X., Chen, J., Cao, Y., Wang, Y., & Cheng, H. (2025). A Simple and Sensitive LC‐MS/MS Method for the Determination of Mobocertinib and Its Metabolite Desmethyl‐Mobocertinib in Human Plasma and Its Application to Clinical Pharmacokinetic Study. Biomedical Chromatography. https://doi.org/10.1002/bmc.6063
Vancouver
Tang F, Hou X, Chen J, Cao Y, Wang Y, Cheng H. A Simple and Sensitive LC‐MS/MS Method for the Determination of Mobocertinib and Its Metabolite Desmethyl‐Mobocertinib in Human Plasma and Its Application to Clinical Pharmacokinetic Study. Biomedical Chromatography. 2025. doi:10.1002/bmc.6063
BibTeX
@article{Tang2025,
author = {Tang, Fan and Hou, Xiaoli and Chen, Jiajie and Cao, Yasen and Wang, Yixia and Cheng, Hong},
title = {A Simple and Sensitive LC‐MS/MS Method for the Determination of Mobocertinib and Its Metabolite Desmethyl‐Mobocertinib in Human Plasma and Its Application to Clinical Pharmacokinetic Study},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.6063}
}
EUVIMED